OBJECTIVE: To probe into the effects of Shexiang Baoxin pills combined with ivabradine on cardiopulmonary function and serological indicators in patients with chronic heart failure（CHF） and chronic obstructive pulmonary disease（COPD）. METHODS: Totally 96 patients with CHF and COPD admitted into the hospital from May 2019 to Aug. 2021 were extracted to be divided into the control group and the observation group via the random number table

with 48 cases in each group. Patients in both groups received the conventional treatment of CHF and COPD. On this basis

the control group was given ivabradine

while the observation group was treated with Shexiang Baoxin pills combined with ivabradine. Both groups were treated for 3 months. Changes of resting heart rate（HR）

cardiopulmonary function indicators [6 minute walking test（6MWT） distance

left ventricular ejection fraction（LVEF）

left ventricular end-diastolic diameter（LVEDD）

forced expiratory volume in one second（FEV

1

）

FEV

1

/forced vital capacity（FEV

1

/FVC） and peak expiratory flow（PEF）] and serum indicators [N-terminal pro-brain natriuretic peptide（NT-proBNP）

high-sensitivity C-reactive protein（hs-CRP） and interleukin-6（IL-6）]

of two groups were compared. The incidence of adverse drug reactions in two groups was counted. RESULTS: After treatment

the resting HR of the observation group was significantly lower than that of the control group

and the 6MWT distance and LVEF were significantly higher than those of the control group

the differences were statistically significant（P

<

0.05）. However

there was no significant difference in LVEDD between two groups（P

>

0.05）. After treatment

the FEV

1

FEV

1

/FVC and PEF of the observation group were significantly higher than those of the control group

the differences were statistically significant（P

<

0.05）. After treatment

the serum levels of NT-proBNP

hs-CRP and IL-6 in the observation group were significantly lower than those in the control group

the differences were statistically significant（P

<

0.05）. During 3 months of treatment

the incidence of adverse drug reactions in the observation group and the control group was respectively 10.42%（5/48） and 12.50%（6/48）

with no statistically significant difference（P

>

0.05）. CONCLUSIONS: The clinical efficacy of Shexiang Baoxin Pills combined with ivabradine in the treatment of patients with CHF and COPD is significant

which can improve the cardiopulmonary function

reduce the levels of serum NT-proBNP and inflammatory factors

with lower incidence of adverse drug reactions.